Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glades Pharmaceuticals, a subsidiary of Stiefel Laboratories, has received FDA approval to market its oral antifungal agent Griseofulvin, the first and only AB rated generic version of Johnson & Johnson's Grifulvin V.
Subscribe to our email newsletter
Griseofulvin oral suspension, USP 125mg/5mL, acts systemically to inhibit the growth of trichophyton, mMicrosporum, and epidermophyton genera of fungi. Major indications for the product are tinea capitis (ringworm of the scalp), tinea corporis (ringworm of the body), tinea pedis (athlete’s foot), tinea unguium (onychomycosis; ringworm of the nails) and tinea cruris (ringworm of the thigh).
“By offering the first AB rated generic version of the widely prescribed Grifulvin V, we will enable healthcare providers and the distribution channel to bring a more cost effective version of this therapy to patients,” said Jeffrey Thompson, president of Glades Pharmaceuticals. “This is an important addition to our product line.”
Glades Pharmaceuticals specializes in the sales and marketing of generic, branded-generic, and branded pharmaceutical products.